LAMPA
Clinical data
Other namesLMP
Legal status
Legal status
  • US: Unscheduled
Identifiers
  • N,7-dimethyl-N-propyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
FormulaC20H25N3O
Molar mass323.440 g·mol−1
3D model (JSmol)
  • CCCN(C)C(=O)C1CN(C2CC3=CNC4=CC=CC(=C34)C2=C1)C
  • InChI=InChI=1S/C20H25N3O/c1-4-8-22(2)20(24)14-9-16-15-6-5-7-17-19(15)13(11-21-17)10-18(16)23(3)12-14/h5-7,9,11,14,18,21H,4,8,10,12H2,1-3H3
  • Key:CZRJGQXHVRNZRZ-UHFFFAOYSA-N

LAMPA (N-methyl-N-propyl lysergamide) is a structural analogue of lysergic acid diethylamide (LSD) that has been studied as a potential treatment for alcoholism.[1] In animal studies, LAMPA was found to be nearly equipotent to ECPLA and MIPLA for inducing a head-twitch response. LAMPA appears to be significantly less potent than LSD in humans, producing little to no noticeable effects at doses of 100 µg.[2]

See also

References

  1. ^ Abramson HA, Rolo A (1967). "Comparison of LSD with methysergide and psilocybin on test subjects." (PDF). In Abramson HA (ed.). The use of LSD in psychotherapy and alcoholism. Bobbs-Merrill Company Inc. pp. 53–57. Retrieved 15 May 2022.
  2. ^ Halberstadt AL, Klein LM, Chatha M, Valenzuela LB, Stratford A, Wallach J, et al. (February 2019). "Pharmacological characterization of the LSD analog N-ethyl-N-cyclopropyl lysergamide (ECPLA)". Psychopharmacology. 236 (2): 799–808. doi:10.1007/s00213-018-5055-9. PMC 6848745. PMID 30298278.
Categories